NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free CSBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.57▼$4.7550-Day Range$9.11▼$10.9652-Week Range$7.19▼$14.68Volume4,222 shsAverage Volume7,236 shsMarket Capitalization$64.01 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrends Get Champions Oncology alerts: Email Address Champions Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside59.2% Upside$7.50 Price TargetShort InterestHealthy0.92% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment1.04Based on 36 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.62 out of 5 starsMedical Sector330th out of 931 stocksBiological Products, Except Diagnostic Industry44th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingChampions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.92% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Champions Oncology has recently decreased by 6.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChampions Oncology has received a 71.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Champions Oncology is -0.81. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 36 news articles for Champions Oncology this week, compared to 13 articles on an average week.MarketBeat Follows1 people have added Champions Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders45.69% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 13.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Champions Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Champions Oncology Stock (NASDAQ:CSBR)Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Read More Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here CSBR Stock News HeadlinesMay 29 at 1:17 AM | msn.comThe rewards of winning the Champions League for Real Madrid, Borussia Dortmund: Trophy, prize money, moreMay 29 at 1:17 AM | nytimes.comAlan Shearer on Joselu and Fullkrug, the unlikely Champions League final forwardsMay 29 at 1:17 AM | msn.comWhere is the Champions League final being played? Everything to know about venue for Real Madrid vs. DortmundMay 29 at 1:17 AM | nytimes.comWhy Champions League finals keep ending 1-0May 28 at 8:16 PM | msn.comCristiano Ronaldo fires a warning to the Kings Cup of Champions Final refereeMay 28 at 8:16 PM | msn.comStill plenty of fear for Real Madrid coach Ancelotti despite Champions League final successesMay 28 at 8:16 PM | msn.comColumbus Crew host team send-off for fans ahead of CONCACAF Champions Cup finalMay 28 at 8:16 PM | msn.comWho is the player with the most Champions League titles in history?May 28 at 8:16 PM | bizjournals.comChampions for Diversity, Equity and Inclusion Awards: Jacquie Foss, Strategies To Empower People Inc.May 28 at 8:16 PM | msn.comUEFA 'would like' Champions League games played in the United States, CBS Sports CEO confirmsMay 28 at 8:16 PM | msn.comThis N.J. native is on a 4-day winning streak on ‘Jeopardy!’ Will he qualify for the Tournament of Champions?May 28 at 8:32 AM | msn.comAidan Morris playing through injury as Columbus Crew head toward Champions Cup finalMay 28 at 8:32 AM | msn.comChampions League final tickets 2024: Prices, date, cheapest seats and cost to buy for UEFA UCL matchMay 28 at 8:32 AM | sports.yahoo.comWhy Arsenal being in Champions League draw Pot 2 is a blessing in disguise for the GunnersMay 28 at 8:32 AM | msn.comWant to watch the Crew in the CONCACAF Champions Cup final in Columbus? Watch party detailsMay 28 at 8:32 AM | msn.comReal Madrid kits for UEFA Champions League final: Jerseys, colors and where to buy for UCL title matchMay 28 at 3:32 AM | nytimes.comCarlo Ancelotti claims he is undecided on Real Madrid goalkeeper choice for Champions League finalMay 28 at 3:32 AM | msn.comWhy Courtois, Lunin dilemma is Ancelotti's biggest Champions League headacheMay 28 at 3:32 AM | msn.comLIV pro wins Senior PGA but gets denied customary PGA Tour Champions exemptionMay 28 at 3:32 AM | reuters.comDays before Champions League final are to enjoy, Ancelotti saysMay 28 at 3:32 AM | msn.comReal Madrid's Champions League aura masks fear behind Super League pursuitMay 28 at 3:32 AM | msn.comOn This Day in 2011: Lionel Messi leads Barcelona to Champions League gloryMay 26 at 11:11 PM | msn.comWill there be extra time, penalties in the Champions League final between Real Madrid and Borussia Dortmund?May 26 at 8:11 AM | nytimes.comBarcelona’s Champions League win felt like a shift in power — but Lyon insist they will be backMay 26 at 3:10 AM | msn.comBarcelona beat Lyon 2-0 to win second straight Women's Champions LeagueSee More Headlines Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/28/2024Next Earnings (Estimated)7/22/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CSBR CUSIPN/A CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$7.50 Low Stock Price Target$7.50 Potential Upside/Downside+59.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net Margins-19.76% Pretax Margin-19.62% Return on Equity-850.72% Return on Assets-32.62% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual Sales$53.87 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book13.85Miscellaneous Outstanding Shares13,590,000Free Float7,383,000Market Cap$64.01 million OptionableOptionable Beta0.40 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesRonnie MorrisPresident Chief Executive Officer & DirectorDavid Barry MillerChief Financial OfficerKarin Abarca HeidemannVice President-Scientific OperationsMichael RitchieChief Commercial OfficerMaria ManciniVice President-PharmacologyKey CompetitorsMetagenomiNASDAQ:MGXZura BioNASDAQ:ZURAInnate PharmaNASDAQ:IPHACandel TherapeuticsNASDAQ:CADLInvivydNASDAQ:IVVDView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Bought 12,380 shares on 4/26/2024Ownership: 0.091%Daniel Newman MendelsonBought 1,000 shares on 1/12/2024Total: $6,500.00 ($6.50/share)Daniel Newman MendelsonBought 2,944 shares on 1/10/2024Total: $18,576.64 ($6.31/share)Daniel Newman MendelsonBought 1,000 shares on 1/8/2024Total: $6,150.00 ($6.15/share)Daniel Newman MendelsonBought 2,000 shares on 1/5/2024Total: $12,180.00 ($6.09/share)View All Insider TransactionsView All Institutional Transactions CSBR Stock Analysis - Frequently Asked Questions Should I buy or sell Champions Oncology stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CSBR shares. View CSBR analyst ratings or view top-rated stocks. What is Champions Oncology's stock price target for 2024? 2 analysts have issued 12-month price targets for Champions Oncology's shares. Their CSBR share price targets range from $7.50 to $7.50. On average, they expect the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 59.2% from the stock's current price. View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts. Are investors shorting Champions Oncology? Champions Oncology saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 56,100 shares, a drop of 6.0% from the April 30th total of 59,700 shares. Based on an average daily volume of 5,000 shares, the days-to-cover ratio is presently 11.2 days. Approximately 0.9% of the shares of the stock are short sold. View Champions Oncology's Short Interest. When is Champions Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our CSBR earnings forecast. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) posted its quarterly earnings results on Tuesday, March, 12th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter. The biotechnology company earned $12.02 million during the quarter. Champions Oncology had a negative net margin of 19.76% and a negative trailing twelve-month return on equity of 850.72%. What is Ronnie Morris' approval rating as Champions Oncology's CEO? 8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL). Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Newman Mendelson and Ronnie Morris. View institutional ownership trends. This page (NASDAQ:CSBR) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.